Biocon Biologics gets EU GMP Certification for new Biologics manufacturing facility in Bengaluru

6 Jul 2022 , 09:39 AM

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

As per the filing, “the facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe”, the  company said.

This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.

“Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with a Honorable Mention, by the International Society for Pharmaceutical Engineering’s (ISPE)”, the pharma-major firm added.

At around 9:40 AM, Biocon was trading at Rs315.45 per share up by Rs1.75 or 0.56% from its previous closing of Rs313.70 per share on the BSE.